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ABSTRACT
Objectives: Sentinel lymph node detection (SLND) has not yet displaced lymphadenectomy, but it is a desired supplemen-
tary technique in cervical cancer surgery. The aim of our study was to identify the sources of SLND failure while performing 
the procedure by injecting blue dye (BD) into the cervix in cases of early-stage cervical cancer (ECC).
Material and methods: We analyzed 27 consecutive ECC patients (FIGO IA2–IB1) who underwent hysterectomy with 
SLND and systematic lymphadenectomy between October 2011 and June 2014. The main inclusion criterion was at least 
unilateral SLND by BD. Predictors of either unilateral or bilateral staining were identified using multinomial logit models 
and a decision tree.
Results: Overall, bilateral staining was achieved in nine patients (33%). Among the factors analyzed, BMI > 23.5 kg/m2 was 
the only factor negatively affecting the quality of SLND using BD (p < 0.02) in the univariable multinomial logit model.  
All patients with BMI < 23.5 kg/m2 and depth of invasion ≥ 15 mm had unilateral mapping.
Conclusions: Both obese and overweight patients are unlikely to achieve optimal SLN staining with BD alone. Although 
some possible reasons are discussed, we believe that further studies are needed to clarify the specific limitations of other 
dyes currently in use.
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INTRODUCTION
Cervical cancer has one of the highest mortality rates 
in the female population. Upon staging and assessing the 
progression of the cancer, it is possible to detect whether 
any sentinel lymph node (SLN) metastasis has occurred. 
To achieve this, a chemical tracer is widely used to map 
the lymph nodes. In addition to direct visualization by the 
physician during surgery, preoperative or intraoperative 
injection of tracers into the cervix is a method for assessing 
the cancer’s spread [1–3]. 
Once excision of the SLN has been performed, it is im-
portant to achieve a histopathological determination of 
metastasis. After histopathological SLN assessment, a deci-
sion must be made regarding whether to perform lymphad-
enectomy or chemoradiation. Overtreatment is desirable to 
avoid in early-stage cervical cancer due to side effects [4, 5].
Bilateral staining (bilateral SLN detection) is effective as 
a credible inference of non-SLN status, and increases metas-
tasis detection, including micrometastases [6]. In contrast, 
unilateral staining is perceived as unsatisfactory for the 
surgeon as well as the pathologist, requiring procedures to 
reduce the risk of false negative inferences on the status of 
lymph nodes (and therefore obligatory lymphadenectomy 
on the non-labeled side of the pelvis).
Many studies focus on the benefits and effectiveness of 
individual methods (sensitivity and specificity), and there 
are few publications on the causes of failure in detecting 
SLN. Reasons that have been identified for failures in map-
ping SLNs include (but are not limited to) the following: 
the type of tracer, whether a single tracer as opposed to 
a tracer combination is used, prior conization, tumor size, 
and patient age [7, 8]. 
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Objectives
The main purpose of this study was to identify the po-
tential causes of false negative results of SLN identification 
methods using intracervical blue dye (BD) injections at early 
stages of cervical cancer on a cohort of patients from our 
previously published research [9]. The second aim of the 
current study was to review the limitations of other dyes 
currently used in SLND procedures in cases of early-stage 
cervical cancer. 
MATERIAL AND METHODS
The participants in this retrospective single institution 
cohort study comprised of 27 patients with early-stage 
cervical cancer (IA2 and IB1) according to the International 
Federation of Gynecology and Obstetrics (FIGO 2009– 
–2018) staging system, who were assessed between 
October 2011 and June 2014. The participants underwent 
either open or laparoscopic radical hysterectomy and lym-
phadenectomy with application of SLND as described in 
detail in our previously published study [9]. With the pa-
tient in the lithotomy position, methylene blue (Methyleen 
blauw, Sterop Pharmacobel, Belgium) was administered 
submucosally in four places in the amount of 1 mL (10 mg) 
per 1 needle puncture (size 22 G, Poly Medicure Ltd., India) 
at 3, 6, 9, and 12 hours, each time about 0.5 cm from the 
edge of the cervical tumor. When the tumor occupied most 
of the cervix, the dye was applied to the free area of the 
cervix at least 0.5 cm from the tumor. Administration was 
performed in an operating room following anesthesia of the 
patient, approximately 15–20 minutes before surgical skin 
incision and approximately 15–25 minutes before opening 
the retroperitoneal space and the identification of SLN(s). 
Lymph nodes were considered sentinel when they were 
blue in color as described by the operator or pathologist, 
or a lymph pathway was identified that led to a specific 
lymph node or nodes.
Lymph nodes were removed, separating the labelled 
(sentinel) from the non-labelled (non-sentinel). Lymph node 
samples embedded in paraffin blocks were tested by serial 
sectioning of 4-micrometre slides every 150 µm and evaluat-
ed by ultrastaging using anti-cytokeratin (CK) AE1/AE3 mon-
oclonal antibodies. Sections were placed on silanized slides, 
two sections from a given section: one for haematoxylin and 
eosin (HE) staining, and the other for antibody reaction CK 
AE1/AE3. The staining directions (unilateral, bilateral) of the 
SLNs were correlated to clinical data [age, body mass index 
(BMI), anamnesis], postoperative tumor size, depth of inva-
sion, the subjective quality of the BD application, the experi-
ence of the physician injecting the BD (novice ≤ 1 year of 
work in gynecological oncology unit, moderate 1 ≥ 5 years, 
and experienced > 5 years), and identification of large 
(> 2 cm) nodes postoperatively (or intraoperatively) in the 
pelvis. Two methods were used for qualitative predictors: 
loglikelihood chi-square test (chi-square ML) and univariate 
multinomial logit models. The second of these was also used 
for quantitative predictors. The normality of distributions 
of the quantitative predictors was verified with the use of 
three different tests: Kolmogorov-Smirnov, Lilliefors and 
Shapiro-Wilk. Results were indicated in the boxplots which 
represent the distribution of the predictors according to the 
directions of the staining. Furthermore, a decision tree was 
used to find the decision algorithm and the importance of 
the predictors.
RESULTS
In nine of the 27 (33%) patients, bilateral pelvic SLN 
staining was achieved. As seen in Table 1, participant data 
on various parameters relevant to the study were collected 
and analyzed based. There were no significant differences 
between the distributions of age, depth of infiltration and 
postoperative size of the tumour or pelvic nodes in terms of 
staining direction. There was also no significant combination 
of predictors shown by the multivariable multinomial logit 
model (Tab. 2). Furthermore, using the univariate ANOVA 
test (Tab. 3), BMI was the only factor shown to be signifi-
cant for staining direction, with a predictive value above 
23.5 kg/m2. The median value of BMI for patients with bilat-
eral staining was lower than in the cases with unilateral stain-
ing and the same applied to the dispersion of BMI in that 
group. In the post-hoc analysis, the BMI differed between the 
left and bilateral successful staining groups, with higher val-
ues occurring in the left-stained group (Tab. 4). Consequent-
ly, we may divide patients into two groups: patients with BMI 
above 23.5 kg/m2 and patients with BMI below this value. 
Patients with BMI below 23.5 kg/m2 achieved bilateral stain-
ing, whereas patients with BMI above 23.5 kg/m2 achieved 
unilateral staining. Furthermore, sub-dividing the group 
with BMI below 23.5 kg/m2 into two groups: 1) those with 
Table 1. Patients characteristics in a cohort of 27 patients
Characteristic Value
Age [years] 23–65 (median 54)
BMI [kg/m2] 19–37 (median 25)
PID in anamnesis (number of patients, %) 1 (3.7)
Previous use of contraceptives (number 
of patients, %) 3* (11)
Previous cervical surgery (number of 
patients, %) 10 (37)




Previous pelvic surgery (number of 
patients, %) 6 (22)
BMI — body mass index; PID — pelvic inflammatory disease; *in one case 
intrauterine device was used, in two cases — oral contraceptives were used
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cancer stromal invasion below 15 mm, and 2) those with 
cancer stromal invasion equal to or greater than 15 mm, thus 
showing that in the first sub-group the bilateral staining was 
dominating, whereas in the second sub-group the staining 
was only unilateral. Returning to the group containing pa-
tients with BMI above 23.5 kg/m2, those patients who were 
younger than 62.5 years typically showed left-sided staining 
compared to the group with BMI above 23.5 kg/m2 which 
showed a trend towards right-sided unilaterality (Fig. 1).
Across the whole study group, those with the histo-
pathological subtype of squamous cell carcinoma and uni-
lateral staining outnumbered those with squamous cell car-
cinoma and bilateral staining, while in the adenocarcinoma 
subtype there was a tendency for unilateral SLN mapping 
(Fig. 2). In the case of previous cervical surgery there were 
much fewer patients with right-sided mapping (only 1 in 
our sample group) than those who had not undergone 
surgery. There were no differences in the numbers of left 
and bilateral staining (Fig. 3). Highly experienced physi-
cians identified bilateral nodes to a greater extent than their 
less-experienced colleagues (Fig. 4). Figure 5 shows lipoma-
tous atrophy found in the pelvic lymph node of the patient 
who had only one side of the pelvis mapped with success.
DISCUSSION
While in our previous study [9] there was no room for 
elaborating the topic in this regard, the aim of our present 
study was to provide possible explanations for the fact that 
bilateral staining occurred in less than half of the study sub-
jects. Predictors of either unilateral or bilateral staining were 
identified using multinomial logit models and a decision 
tree. The main result of the study shows that both over-
weight and obese patients are unlikely to achieve optimal 
SLN staining with BD alone. One of the reasons for that is 
the lateralization of the SLN staining that occurs with dye. 
It is increasingly important to identify the precise extent of 
lymph node metastasis in order to avoid any over-resection 
of healthy tissue, in consideration of patients’ quality of life 
after treatment. The dye markers, among which blue dyes 
are mainly used, included: aniline derivatives (patent blue 
Table 2. Factors linked with direction of mapping
Predictors loglikelihood chi-square test p value
Univariable multinomial logit model
p value
Previous cervical surgery 4.584641 df = 2 p = 0.10103 0.101
Previous pelvic surgery 1.357020 df = 2 p = 0.50737 0.507
Histological type 7.379678 df = 4 p = 0.11713 0.025
The quality of the marker’s application 4.603175 df = 4 p = 0.33049 0.100
Experience 1.826553 df = 2 p = 0.40121 0.401
Large lymph nodes [> 2 cm in greatest dimension] 5.265428 df = 2 p = 0.76853 0.769
Age [years] 0.126
BMI [kg/m2] 0.018
Size of postoperative tumor [cm] 0.108
Depth of infiltration [mm] 0.396
BMI — body mass index
Table 3. Univariate ANOVA tests for quantitative predictors
Variable
Levene Test (for variance) ANOVA
F p value F p value
Age 0.246028 0.783849 2.099059 0.144509
Body mass index 0.663798 0.524092 3.739278 0.038580
Depth of infiltration 1.182010 0.323888 0.872018 0.430938
Postoperative tumor size [cm]* 0.9100886 0.6344
*Kruskal Wallis test
Table 4. Post-hoc tests for increased weight
Direction of 
staining







left {1} 0.046760 0.929121
bilateral {2} 0.046760 0.098288
right {3} 0.929121 0.098288
BMI — body mass index
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V, Patentblau — V; alfazurin, Alphazurin, lymphazurin, Lym-
phazurin) and methylene blue. The choice of methylene blue 
was dictated by the practice used in the clinic. Methylene 
blue is a widely available and relatively inexpensive dye, that 
does not require additional facilities, and in our study, it was 
used as a supplementary diagnostic procedure for planned 
lymphadenectomy. Our study was designed to evaluate 
the efficacy of methylene blue dye that was being admin-
istered in a single institution in a cohort of patients with 
early-stage cervical cancer. Only two factors proved to be 
Decision Tree
Method C&RT
ID = 1 N = 25
left
ID = 2 N = 9
bilateral
ID = 4 N = 7
bilateral
ID = 5 N = 2
left
ID = 3 N = 16
left
ID = 6 N = 1
right
ID = 7 N = 6
bilateral
ID = 8 N = 1
left
ID = 9 N = 1
right
ID = 10 N = 11
left
ID = 11 N = 5
right
OBESITY  (BMI)
≤ 23.5 > 23.5
Depth  of inltration
≤ 15 > 15
Depth of in ltration
≤ 5.5 > 5.5
Large (> 2 cm in greatest dim) lymph node
no yes
AGE
≤ 62.5 > 62.5
left    
bilateral
right
Figure 1. Decision tree comprising obestity, age and depth of infiltration; BMI — body mass index; ID — node numbers (there are 9 different types 
of lymph nodes in total in the statistical analysis); N — is the number of units (patients in the node)
Figure 2. The interaction plot showing distributions of number of 
patients simultaneously due to histological type and direction of 
color
glandular squamous different





















Figure 3. The interaction plot showing distributions of number 
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significant causes of lateralizing hemipelvis staining: a BMI 
higher than 23.5 kg/m2 and histopathological subtypes of 
cervical carcinoma. Other analyzed factors such as gyneco-
logical anamnesis, age, experience of physician injecting the 
BD, size of tumor, size of lymph nodes, and histological type 
were insignificant in relation to the quality of detection of 
reactive lymph nodes.
The techniques for labelling SLN involve administering 
the tracers in a manner that allows them to reach from the 
vicinity of the primary tumor or from the primary tumor 
itself to each lymph node connected to it by a lymph vessel. 
Among those currently used, there are dye-based, isotopic 
either with or without lymphoscintigraphy, and dye-iso-
topic methods; and in the field of clinical research there 
are isotope-free methods, either using the paramagnetic 
properties of tissue or specifically designed markers show-
ing the reaction to infrared light (i.e., indocyanine green, 
ICG). Physicians prefer dye tracers for its simplicity, as it is 
injected pre-operatively directly into the four quadrants or 
two sides of the uterine cervix under general anesthesia, and 
there is no need to consult a nuclear medicine department 
as is the case when technetium-99m-labeled human serum 
albumin is injected. These aspects offer comfort and confi-
dence. Other reasons for preferring dye tracers over other 
types are their lower cost, that there is no need for special 
visualization systems, and no need for a central pharmacy to 
prepare the dye. However, the rate of false negative results 
associated with the use of BD requires consideration [10–13].
Overweight/obesity is a worldwide problem that con-
tinues to grow, especially in developed countries. Abnormal 
BMI not only increases the risk of many neoplastic diseases, 
but also affects the outcomes of many medical procedures.
A substantial proportion of patients undergoing surgery 
for cervical cancer are overweight or obese. This is an issue 
when one considers the recent European Society of Gyne-
cological Oncology recommendations that say open surgery 
in cervical cancer is the gold standard for the treatment 
of patients with this type of cancer [14]. Among possible 
reasons that overweight and obesity affect the results of 
sentinel node labeling, are the dispersion of the chemical 
tracer across a greater body surface area (i.e., too-low doses 
are administered) and metabolism. Recent studies have 
shown that the use of ICG can bypass obesity-related prob-
lems with SLN staining [15, 16]. Although obesity itself is 
defined as a BMI value of above 30 kg/m2, our study showed 
an unfavorable trend beginning as low as 23.5 kg/m2, mean-
ing that the risk of false negative outcomes increased at 
values well below the officially recognised lower threshold 
of overweight status. As studies have shown that this issue 
can partly be bypassed with the application of ICG, the use 
of this dye tracer is advisable. However, it must be noted 
that even with the application of ICG, completely bypassing 
the effects of overweight/obesity is not possible since this 
tracer has shown increased false negative results at elevated 
BMIs (although the BMIs producing negative results for ICG 
are higher than those for methylene and isosulfan blue 
dyes). The conclusion to be drawn is that although these 
tracers provide false-negative results at higher BMIs, the 
false-negative rates are considerably lower when using 
ICG than when applying methylene or isosulfan blue trac-
ers [17, 18]. The reasons for poor bilateral staining results 
with BD may be because in cases where there are patients 
with a higher BMI and relatively low expertise of those con-
ducting the procedure, and the difficulty of gaining a clear 
view of the surgical field (i.e., more fat tissue, more rapid 
tracer penetration into this tissue), it becomes easier to 


























Figure 4. The interaction plot showing distributions of number of 
patients simultaneously due to experience of physician and direction 
of color
Figure 5. Lipomatous atrophy in the pelvic lymph node; A pelvic 
lymph node in a patient who has overweight (26 kg/m2) and a sentinel 
lymph node mapping failure. The lymph node begins to turn off 
functionally from the lymphatic plexus and lymph ceases to flow 
through part of the node. Lipomatous atrophy is formed in place of 
the structure of the lymph node (asterisk). However, preexistent lymph 
node structure (arrows) does not exclude lymph node metastasis
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(i.e., incomplete application, technical difficulties). In Table 
5, we have provided a comparison of different lymph node 
labelling method [7, 17–20]. Although lipomatous atrophy 
in the lymph nodes has not been linked with obesity in the 
literature, one may consider such an association. In several 
patients with hemi-pelvis mapping, we observed this con-
dition of the lymph nodes (2–5 per patient on the contra-
lateral side), while in the group with bilateral staining we 
found such lymph nodes less frequently (0–2 per patient). 
The number of patients in this study is limited and the condi-
tion of lipomatous atrophy is too common to draw specific 
conclusions on this topic.
CONCLUSIONS
This study has some limitations. One limitation was 
related to the low number of samples. Having studied only 
27 patients, the results may have produced inaccuracies 
which may have been avoided if the number of samples 
was greater. Another limitation was related to the relatively 
high number of physicians involved in injecting the dye. 
The physicians possessed different levels of experience and 
Table 5. Methods for sentinel lymph nodes mapping in gynecological oncology





It does not require 
advanced facilities of the 
nuclear medicine ward, 
avoiding radiation
Demanding technique (role 
of experience), possibility of 
allergic reactions, tattoos, 
quantitative measurement 
impossible
Dependence on favorable operational 
field exposure, avoiding dilution of 
the dye (rapid absorbing to lymphatic 
pathway), blue dye dosage and site 
of injection, the time between dye 
injection and the operative procedure 
(risk of moving of BD on to the non-
sentinel lymph nodes) 
Jarruwale et al. 
2012
With the use of 
infrared light 
(fluorescent dye)
It does not require 
advanced facilities of the 
nuclear medicine ward, 
avoiding radiation
Requires a special 
intraoperative detection 
system; the possibility of 
an allergic reaction, tattoos
Spilling from the lymphatic system 
during lymph node dissection due 
to small size of particles, presence of 
metastatic lymph nodes
Cheng-Yen Lai et al. 






and specificity in 
the detection of SLN 
compared to the 
dye technique itself, 
quantification of uptake
Expensive, requiring 
(less than in the case of 
lymphoscintigraphy) 
facilities of the nuclear 
medicine facility (qualified, 
interdisciplinary staff), 
contraindicated in pregnant 
women and lactation 
Primary tumor site, scanned timing 
before SLN can uptake radioactive 
matters, different infusion areas, size of 
investigating materials




High sensitivity and 
specificity in SLN 
detection, quantitative 
uptake assessment, 
useful in so-called 
„Learning curve”, testing 
new combinations, e.g. 
Tilmanocept*
Expensive, requiring nuclear 
medicine facilities (qualified, 
interdisciplinary staff), having 
a gamma camera)*
Primary tumor site, scanned timing 
before SLN can uptake radioactive 
matters, different infusion areas, size of 
investigating materials
Jarruwale et al. 
2012, Surasi et al. 
2015
Paramagnetic
Low cost and outlay 
of hardware facilities 
compared to the results 
obtained, quantification 
of uptake
Requiring nuclear medicine 
facilities (qualified, 
interdisciplinary staff, having 
the appropriate detector)
Not yet available for cervical cancer
*for tilmanocept, no agreed good practice for cervical cancer; BD — blue dye; SLN —sentinel lymph node
expertise. The third limitation relates to the fact that blue 
dye is no longer the preferred method for detecting SLNs as 
other dye tracers have been shown to be superior. However, 
that was not the case several years ago when the study was 
commenced. The fourth and last concern is the decision 
tree used. However, it is of importance to remember that 
the decision tree is not a statistical test but simply a system 
for the division of units based on a chosen classification 
measure. It can occur that it shows the rule which exists in 
the sample but not in the population. Thus, in our opinion it 
is helpful to use decision trees to formulate rather than prove 
hypotheses. Due to the small sample size, we were unable 
to find excessive rules and deviations since a decision tree 
easily creates individual groups. Nevertheless, we believe 
that further analyses that take into consideration obese and 
non-obese patients would have scientific value.
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